{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:12:27Z","timestamp":1788797547572,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Syphilis is a sexually transmitted disease caused by\n                      <jats:italic toggle=\"yes\">Treponema pallidum<\/jats:italic>\n                      . Minocycline, a representative tetracycline derivative, has the greatest antimicrobial activity among all tetracyclines. There are few reports about treating syphilis with minocycline because there is a lack of efficacy data from controlled trials. We compared the rates of serological cure in patients with early syphilis who were treated with minocycline or benzathine penicillin G (BPG).\n                    <\/jats:p>\n                    <jats:p>During the study period, a total of 40 syphilis patients received the BPG treatment, which was a single intramuscular dose of 2.4 million units of BPG, and 156 patients were treated with minocycline; 77 patients were placed in the 2-week, standard minocycline therapy group and received 100\u200amg of minocycline orally, twice daily for 14 days, and 79 patients were placed in the 4-week, lengthened minocycline therapy group and received 100\u200amg of minocycline orally, twice daily for 28 days. The outcome of interest was the rate of serological cure in these patients.<\/jats:p>\n                    <jats:p>\n                      At the end of the 2-year follow-up, the serological cure rate of the 4-week, lengthened minocycline therapy group (87.34%) was higher than that of both the 2-week, standard minocycline therapy group (72.73%) and the BPG treatment group (77.50%). In addition, the curative effect of the 4-week, lengthened minocycline therapy was significantly greater than that of the 2-week, standard minocycline therapy in patients who were aged &gt;40 years; exhibited an initial rapid plasma reagin titer \u22651: 32; or exhibited secondary syphilis (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a=\u200a0.000, 0.008, 0.000; &lt;0.05).\n                    <\/jats:p>\n                    <jats:p>Minocycline appears to be an effective agent for treating early syphilis, especially when applied as a 4-week, lengthened therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000005773","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T14:06:09Z","timestamp":1483020369000},"page":"e5773","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Could lengthening minocycline therapy better treat early syphilis?"],"prefix":"10.1097","volume":"95","author":[{"given":"Li-Li","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan-Zhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-55-20260907","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12879-015-1028-3","article-title":"Emerging trends and persistent challenges in the management of adult syphilis","volume":"15","author":"Tuddenham","year":"2015","journal-title":"BMC Infect Dis"},{"key":"R2-55-20260907","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S0140-6736(07)60044-0","article-title":"Syphilis resurgent in China","volume":"369","author":"Fisman","year":"2007","journal-title":"Lancet"},{"key":"R3-55-20260907","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(07)60074-9","article-title":"Syphilis in China: results of a national surveillance programme","volume":"369","author":"Chen","year":"2007","journal-title":"Lancet"},{"key":"R4-55-20260907","doi-asserted-by":"crossref","first-page":"e22768","DOI":"10.1371\/journal.pone.0022768","article-title":"HIV and syphilis co-infection increasing among men who have sex with men in China: a systematic review and meta-analysis","volume":"6","author":"Chow","year":"2011","journal-title":"PLoS One"},{"key":"R5-55-20260907","doi-asserted-by":"crossref","first-page":"e0149401","DOI":"10.1371\/journal.pone.0149401","article-title":"Time series modelling of syphilis incidence in China from 2005 to 2012","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"R6-55-20260907","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/01.OLQ.0000109941.60065.65","article-title":"Evaluation of a Treponema pallidum-specific IgM enzyme immunoassay and Treponema pallidum western blot antibody detection in the diagnosis of maternal and congenital syphilis","volume":"31","author":"Rawstron","year":"2004","journal-title":"Sex Transm Dis"},{"key":"R7-55-20260907","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1258\/ijsa.2007.007258","article-title":"Primary syphilis","volume":"19","author":"Eccleston","year":"2008","journal-title":"Int J STD AIDS"},{"key":"R8-55-20260907","first-page":"1","article-title":"Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015","volume":"64","author":"Workowski","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"R9-55-20260907","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/jdv.12734","article-title":"European guideline on the management of syphilis","volume":"28","author":"Janier","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R10-55-20260907","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3855\/jidc.3013","article-title":"Early syphilis: serological treatment response to doxycycline\/tetracycline versus benzathine penicillin","volume":"8","author":"Li","year":"2014","journal-title":"J Infect Dev Ctries"},{"key":"R11-55-20260907","first-page":"543","article-title":"Curative effect observation of minocycline for the treatment of 36 cases of early syphilis","volume":"23","author":"Zhongfa","year":"2007","journal-title":"China J Leprosy Skin Dis"},{"key":"R12-55-20260907","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/cid\/cir671","article-title":"Predictors of serological cure and Serofast state after treatment in HIV-negative persons with early syphilis","volume":"53","author":"Se\u00f1a","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R13-55-20260907","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.7326\/0003-4819-114-12-1005","article-title":"Serologic response to treatment of infectious syphilis","volume":"114","author":"Romanowski","year":"1991","journal-title":"Ann Intern Med"},{"key":"R14-55-20260907","doi-asserted-by":"crossref","first-page":"e70102","DOI":"10.1371\/journal.pone.0070102","article-title":"Factors associated with serological cure and the serofast state of HIV-negative patients with primary, secondary, latent, and tertiary syphilis","volume":"8","author":"Tong","year":"2013","journal-title":"PLoS One"},{"key":"R15-55-20260907","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/OLQ.0b013e3181b6f0cc","article-title":"Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California","volume":"37","author":"Horberg","year":"2010","journal-title":"Sex Transm Dis"},{"key":"R16-55-20260907","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.imlet.2006.07.006","article-title":"Age-associated changes within CD4+ T cells","volume":"107","author":"Kovaiou","year":"2006","journal-title":"Immunol Lett"},{"key":"R17-55-20260907","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis757","article-title":"Serological response to treatment of syphilis according to disease stage and HIV status","volume":"55","author":"Knaute","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R18-55-20260907","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/cid\/cis918","article-title":"Response to therapy following retreatment of serofast early syphilis patients with benzathine penicillin","volume":"56","author":"Sefx2","year":"2013","journal-title":"Clin Infect Dis"},{"key":"R19-55-20260907","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM199707313370504","article-title":"A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group; 1997","volume":"337","author":"Rolfs","year":"1997","journal-title":"N Engl J Med"},{"key":"R20-55-20260907","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/sti.2006.021402","article-title":"Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics","volume":"83","author":"Ghanem","year":"2007","journal-title":"Sex Transm Infect"},{"key":"R21-55-20260907","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.annemergmed.2004.06.002","article-title":"Update on emerging infections: news from the Centers for Disease Control and Prevention. Brief report: azithromycin treatment failures in syphilis infections: San Francisco, California, 2002\u20132003","volume":"44","author":"Chen","year":"2004","journal-title":"Ann Emerg Med"},{"key":"R22-55-20260907","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1001\/jama.1980.03300500026022","article-title":"Treatment of primary and secondary syphilis. Serological response","volume":"243","author":"Fiumara","year":"1980","journal-title":"JAMA"},{"key":"R23-55-20260907","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archderm.1973.01620260013003","article-title":"Dose-related seroreversal in syphilis","volume":"108","author":"Durst","year":"1973","journal-title":"Arch Dermatol"},{"key":"R24-55-20260907","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/0956462413480721","article-title":"Enhanced therapy for primary and secondary syphilis: a longitudinal retrospective analysis of cure rates and associated factors","volume":"24","author":"Tittes","year":"2013","journal-title":"Int J STD AIDS"},{"key":"R25-55-20260907","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/archinte.160.18.2819","article-title":"The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance","volume":"160","author":"Lee","year":"2000","journal-title":"Arch Intern Med"},{"key":"R26-55-20260907","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10916-009-9391-5","article-title":"Using health smart cards to check drug allergy history: the perspective from Taiwan's experiences","volume":"35","author":"Hsu","year":"2011","journal-title":"J Med Syst"},{"key":"R27-55-20260907","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.amjmed.2008.04.042","article-title":"Primary syphilis: serological treatment response to doxycycline\/tetracycline versus benzathine penicillin","volume":"121","author":"Wong","year":"2008","journal-title":"Am J Med"},{"key":"R28-55-20260907","doi-asserted-by":"crossref","first-page":"v178","DOI":"10.1093\/ofid\/ofv178","article-title":"Minocycline as A Substitute for Doxycycline in Targeted Scenarios: A Systematic Review","volume":"2","author":"Carris","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"R29-55-20260907","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br J Pharmacol"},{"key":"R30-55-20260907","first-page":"789","article-title":"Tetracyclines Med Clin North A","volume":"79","author":"Klein","year":"1995","journal-title":"m"},{"key":"R31-55-20260907","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","article-title":"Safety of doxycycline and minocycline: a systematic review","volume":"27","author":"Smith","year":"2005","journal-title":"Clin Ther"},{"key":"R32-55-20260907","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jama.1972.03200100039008","article-title":"Minocycline in the treatment of venereal disease","volume":"220","author":"Velasco","year":"1972","journal-title":"JAMA"},{"key":"R33-55-20260907","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1056\/NEJM199710303371817","article-title":"Minocycline for symptomatic neurosyphilis in patients allergic to penicillin","volume":"337","author":"De Maria","year":"1997","journal-title":"N Engl J Med"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:03:34Z","timestamp":1788797014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201612300-00055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":33,"journal-issue":{"issue":"52","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000005773","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}